Topics
Glioblastoma | Treatment | Clinical trials | Radiosensitizers
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Radiosensitizers
Pepper NB, Eich HT, Müther M,
Oertel M, Rehn S, Spille DC, Stummer W.
ALA-RDT
in GBM: protocol of the phase I/II dose escalation trial of
radiodynamic therapy with 5-Aminolevulinic acid in patients with
recurrent glioblastoma.
Radiat
Oncol. 2024 Jan
22;19(1):11. doi:
10.1186/s13014-024-02408-7. PMID:
38254201. Interventional
study protocol. ˍ
Skeie BS, Sleire L, Grüner ER, Bragstad S, Heggdal JI, Eide
GE, Enger PØ.
Phase I trial
combining sulfasalazine and gamma knife radiosurgery for recurrent
glioblastoma.
MethodsX.
2026 Apr 22;16:103915. doi:
10.1016/j.mex.2026.103915. PMID:
42089023. Trial
registration ID: NCT04205357. ˍ
Skeie BS, Craig-Craven AR, Grüner ER, Biermann M, Riemer F,
Bragstad S, Sarowar S, Behbahani M, Sleire L, Schwarzlmüller
T, Goplen D, Heggdal JI, Knisely JPS, Schulder M, Eide GE, Filippi
CG, Enger PØ.
Phase 1
dose-escalation trial combining sulfasalazine and stereotactic
radiosurgery in patients with recurrent glioblastoma.
Redox
Biol. 2026 May 30;95:104241. doi:
10.1016/j.redox.2026.104241. PMID:
42229231. Trial
registration ID: NCT04205357. ˍ